FDA approves Acuvue ortho-K lenses for myopia control
Johnson & Johnson Vision announced that the FDA approved Acuvue Abiliti Overnight orthokeratology contact lenses, designed to help manage myopia.
“The FDA approval of Abiliti Overnight marks an important milestone in our commitment to help change the trajectory of eye health and reshape the future of children with myopia,” Xiao-Yu Song, MD, PhD, global head of research and development at Johnson & Johnson Vision, said in the release. “We look forward to supporting parents and eye care professionals in their care of children with comprehensive resources, starting with Abiliti Overnight Therapeutic Lenses, and continuing with additional products and services to address the progression of myopia.”
According to the release, clinical studies showed Abiliti Overnight to be safe and effective with an average reduction in axial elongation by 0.28 mm over a 2-year period. A design for astigmatism is also available.
Johnson & Johnson Vision also noted in the release that each annual purchase of an Abiliti product will provide a free comprehensive eye health exam to a child in need through the Sight for Kids nonprofit program.
The company stated that it expects the Abiliti Overnight ortho-K lens to be available in the U.S. by the end of 2021.